Capricor Says FDA Used ‘Obsolete’ Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document — TradingView News
Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed […]









